Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
Completed
Cellceutix Corporation
Phase 2
The purpose of this study is to determine the safety and efficacy of three different dosing
regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.
This study will aid in selecting the appropriate dose of brilacidin for later stage studies.
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Completed
Cellceutix Corporation
Phase 2
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation
regimens used to treat cancer. This study examines the investigational drug brilacidin and
its possible application in prevention of oral mucositis in patients undergoing
chemoradiation for treatment of head and neck cancer.
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Completed
Innovation Pharmaceuticals, Inc.
Phase 2
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation
regimens used to treat cancer. This study examines the investigational drug brilacidin and
its possible application in prevention of oral mucositis in patients undergoing
chemoradiation for treatment of head and neck cancer.
A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
Completed
Innovation Pharmaceuticals, Inc.
Phase 1
This is a single-centre, blinded, randomized, placebo controlled, dose escalation study. Up
to 9 healthy male volunteers will participate in the study. This study is designed to
investigate the use of delayed release tablets for colonic delivery of Brilacidin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
